An interventional study of Comprehensive Self-Management Intervention and Control in Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn Disease, sponsored by University of Washington. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University of Washington · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 155th largest by enrollment of the 327 interventional ones that give a count, is one of 19 that started in 2023, is one of 131 with no phase, and was the 374th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Stanford University · Sites in United States
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 19 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
University of Washington has 3 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
43 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT06188793University of MichiganVirtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients | 2026-12 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
Add all 43 to your calendar (.ics) → With an account.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to test the feasibility, acceptability, and preliminary efficacy of a comprehensive self-management (CSM) intervention for people with inflammatory bowel disease (IBD). The CSM-IBD intervention is an adaption of the CSM intervention initially developed for individuals with irritable bowel syndrome. The intervention has eight sessions which cover an introduction to IBD, symptom tracking, cognitive behavioral strategies, relaxation, sleep, diet, and pain management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The 8 week intervention is delivered online with a brief weekly check-in with a registered nurse.
Behavioral: Comprehensive Self-Management Intervention
The control group will receive standard care without the comprehensive self-management intervention.
Other: Control
In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
The control group will receive standard care.
Recruitment Feasibility
Percentage comprised of number of participants enrolled divided by the number of participants approached.
Time frame: From screening to enrollment, an average of one month
Intervention Feasibility
Measured with the Feasibility of Intervention Measure (FIM) in which participants respond to four questions on a 5-point Likert scale from completely disagree (1) to completely agree (5). Range: 1 to 5. A higher score indicates greater feasibility.
Time frame: 3 months
Change in Quality of Life
Short Inflammatory Bowel Disease Questionnaire is a 10-item questionnaire which evaluates quality of life. Participants respond on a 7-item Likert scale from all the time to none of the time. Total score range: 10 to 70. A higher score indicates greater quality of life.
Time frame: Baseline, 3 months, 6 months
Change in Abdominal Pain Symptoms
Abdominal pain was measured using a numeric rating scale where participants report the severity of the symptom from not present (0) to worst possible (10).
Time frame: Baseline, 3 months, 6 months
Self-Efficacy for Managing Chronic Disease
A 6-item self-report scale. Participants report ranging from not at all confident to totally confident. Range: 1-10. A higher score indicates greater self-efficacy
Time frame: Baseline, 3 months, 6 months
Index of Self-Regulation
A 9-item scale to measure individual's level of self-regulation. Range: 0-36. A higher score indicates greater self-regulation.
Time frame: Baseline, 3 months, 6 months
Patient Activation Measure
A 13-item scale which assess patient's beliefs, knowledge and confidence in managing their health. Range: 0-100. A higher score indicates greater activation.
Time frame: Baseline, 3 months, 6 months
Fecal Calprotectin
Number of Participants with Inactive Disease based on fecal calprotectin (\<150 µg/g) assessed using ELISA.
Time frame: Baseline, 3 months
| Milestone | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Started | 36 | 19 |
| Completed | 29 | 18 |
| Not completed | 7 | 1 |
Percentage comprised of number of participants enrolled divided by the number of participants approached.
| Participants | All Participants Approached |
|---|---|
| Recruitment Feasibility | 55 |
Measured with the Feasibility of Intervention Measure (FIM) in which participants respond to four questions on a 5-point Likert scale from completely disagree (1) to completely agree (5). Range: 1 to 5. A higher score indicates greater feasibility.
| Scores on a scale | Comprehensive Self-Management |
|---|---|
| Intervention Feasibility | 4.34 ± 0.6 |
Short Inflammatory Bowel Disease Questionnaire is a 10-item questionnaire which evaluates quality of life. Participants respond on a 7-item Likert scale from all the time to none of the time. Total score range: 10 to 70. A higher score indicates greater quality of life.
| Score on a scale | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Baseline | 44.0 ± 9.6 | 46.4 ± 11.3 |
| 3 months post-randomization change score | 4.6 ± 9.4 | 1.6 ± 6.1 |
| 6 months post-randomization change score | 6.1 ± 8.2 | 1.7 ± 6.7 |
Abdominal pain was measured using a numeric rating scale where participants report the severity of the symptom from not present (0) to worst possible (10).
| Units on a scale | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Baseline | 3.6 ± 2.2 | 4.2 ± 2.2 |
| 3 months post-randomization change score | 0.1 ± 2.3 | -0.8 ± 1.5 |
| 6 months post-randomization change score | -0.4 ± 2.5 | -0.3 ± 1.8 |
A 6-item self-report scale. Participants report ranging from not at all confident to totally confident. Range: 1-10. A higher score indicates greater self-efficacy
| Score on a scale | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Baseline | 5.9 ± 1.9 | 5.6 ± 2.2 |
| 3 months post-randomization change score | 0.6 ± 1.8 | 0.5 ± 1.4 |
| 6 months post-randomization change score | 1.4 ± 2.3 | 0.4 ± 1.6 |
A 9-item scale to measure individual's level of self-regulation. Range: 0-36. A higher score indicates greater self-regulation.
| Score on a scale | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Baseline | 23.0 ± 5.6 | 23.9 ± 3.4 |
| 3 months post-randomization change score | 4.7 ± 6.4 | 0.3 ± 4.1 |
| 6 months post-randomization change score | 4.9 ± 5.5 | 1.0 ± 4.5 |
A 13-item scale which assess patient's beliefs, knowledge and confidence in managing their health. Range: 0-100. A higher score indicates greater activation.
| Score on a scale | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Baseline | 58.5 ± 13.7 | 62.0 ± 9.9 |
| 3 months post-randomization change score | 10.3 ± 14.6 | 2.6 ± 10.9 |
| 6 months post-randomization change score | 14.4 ± 13.3 | 4.3 ± 12.5 |
Number of Participants with Inactive Disease based on fecal calprotectin (\<150 µg/g) assessed using ELISA.
| Participants | Comprehensive Self-Management | Usual Care Group |
|---|---|---|
| Baseline | 28 | 16 |
| 3 months post-randomization | 20 | 13 |
Collected over from enrollment until the end of follow up, an average of 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Comprehensive Self-Management | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Usual Care Group | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Age, Continuous(Years) | Comprehensive Self-Management | Usual Care Group | Total |
|---|---|---|---|
| Mean | 40.9 ± 12.3 | 35.3 ± 12.1 | 39.0 ± 12.4 |
| Sex: Female, Male(Participants) | Comprehensive Self-Management | Usual Care Group | Total |
|---|---|---|---|
| Female | 28 | 16 | 44 |
| Male | 8 | 3 | 11 |
| Race (NIH/OMB)(Participants) | Comprehensive Self-Management | Usual Care Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 28 | 11 | 39 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Quality of Life(Scores on a scale) | Comprehensive Self-Management | Usual Care Group | Total |
|---|---|---|---|
| Mean | 44.0 ± 9.6 | 46.4 ± 11.3 | 44.8 ± 10.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2023 to primary completion in Sep 2025, 30 months.
Results were first posted in Sep 2026, 11 months after primary completion.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 30 months is above that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.